HOME Top Market Reports Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020

Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020

By: marketsandmarkets.com
Publishing Date: December 2015
Report Code: BT 3981

 

  Speak to Analyst Enquiry Before Buying  
purchase report
download pdf  request for customisation


The global human insulin market is poised to reach ~USD 39.13 Billion by 2020 growing at a CAGR of 8.1% from 2015 to 2020. Market growth can be attributed to factors such as growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. However, stringent regulatory requirements for product approval are restraining the growth of human insulin market. In addition, high product manufacturing costs is posing significant challenges for market growth.

North America (particularly the U.S.) is expected to hold the largest share of market during the forecast period. Factors such as significant patent protection for several human insulin biosimilar brands in the U.S., continuous updation of medical reimbursement guidelines in the U.S. for diabetes treatment, and extensive & well-established distribution network of market players for human insulin products are driving the growth of the North American human insulin market.

In 2014, Novo Nordisk A/S (Denmark) dominated the global market. Over the past three years, the company adopted product commercialization, geographic expansion, and awareness campaigns as key business strategies to maintain its position in the market. The other key players in this market include Sanofi (France), Eli Lilly and Company (U.S.), Biocon Ltd. (India), Julphar (U.A.E.), Ypsomed AG (Switzerland), Becton, Dickinson and Company (U.S.), Wockhardt Ltd. (India), B. Braun Meselgen AG (Switzerland), and Biodel Inc. (U.S.), among others.

Scope of the report

This research report categorizes the human insulin market into the following segments and subsegments:

Human Insulin Market, By Product

  • Drugs
  • Delivery Devices

Human Insulin Drugs Market, By Product Type

  • Insulin Analogs and Biosimilars
    • Rapid-acting
    • Long-acting
    • Premixed
  • Human Insulin Biologics
    • Short-acting
    • Intermediate-acting
    • Premixed

Human Insulin Drugs Market, By Brand

  • Insulin Analogs and Biosimilars
    • Lantus
    • NovoRapid/Novolog
    • Humalog
    • Other Brands
  • Human Insulin Biologics
    • Actrapid, Insulatard, and Mixtard
    • Humulin
    • Insuman

Human Insulin Delivery Devices Market, By Product Type

  • Pens
    • Reusable
    • Disposable
  • Pen Needles
    • Standard
    • Safety
  • Syringes

Human Insulin Market, By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Rest of Europe (RoE)
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific (RoAPAC)
  • Rest of the World (RoW)

Table of Contents

1 Introduction (Page No. - 16)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 19)
    2.1 Research Data
           2.1.1 Secondary Data
                    2.1.1.1 Key Data From Secondary Sources
           2.1.2 Primary Data
                    2.1.2.1 Key Data From Primary Sources
                    2.1.2.2 Breakdown of Primaries
    2.2 Market Size Estimation
           2.2.1 Bottom-Up Approach
           2.2.2 Top-Down Approach
    2.3 Market Breakdown and Data Triangulation
    2.4 Research Assumptions
           2.4.1 Assumptions

3 Executive Summary (Page No. - 27)
    3.1 Introduction
    3.2 Current Market Scenario
    3.3 Future Outlook
    3.4 Conclusion

4 Premium Insights (Page No. - 32)
    4.1 Global Market (2015–2020)
    4.2 Global Market Size, By Product (2015)
    4.3 Global HI Drugs Market Size, By Product Type (2015-2020)
    4.4 Global HI Drugs Market Size, By Brand (2014)
    4.5 Global HI Delivery Devices Market Size, By Type (2015-2020)
    4.6 Global Market Size, By Region (2015-2020)

5 Market Overview (Page No. - 38)
    5.1 Introduction
    5.2 Market Segmentation
    5.3 Market Evolution
    5.4 Market Dynamics
           5.4.1 Key Market Drivers
                    5.4.1.1 Growth in the Number of Diabetic Patients
                    5.4.1.2 Increasing Population Exposure to Key Risk Factors Leading to Diabetes
                    5.4.1.3 Rising Market Demand for HI Analogs
                    5.4.1.4 Technological Advancements in HI Delivery Devices
                    5.4.1.5 Favorable Medical Reimbursement Scenario in Developed Countries
           5.4.2 Key Market Restraints
                    5.4.2.1 Stringent Regulatory Requirements for Product Approval
           5.4.3 Key Market Opportunities
                    5.4.3.1 Emerging Markets
                    5.4.3.2 Expected Patent Expiry of Key HI Drugs
           5.4.4 Key Market Challenge
                    5.4.4.1 High Product Manufacturing Costs

6 Industry Insights (Page No. - 48)
    6.1 Introduction
    6.2 Industry Trends
           6.2.1 Growing Market Demand for HI Pens
           6.2.2 Increasing Market Focus on the Pipeline Development of Novel Human Insulin Therapies
    6.3 Pipeline Analysis
           6.3.1 By Company
           6.3.2 By Clinical Trial Phase
           6.3.3 Porter’s Five Force Analysis
                    6.3.3.1 Threat From New Entrants
                    6.3.3.2 Threat From Substitutes
                    6.3.3.3 Bargaining Power of Buyers
                    6.3.3.4 Bargaining Power of Suppliers
                    6.3.3.5 Intensity of Competitive Rivalry

7 Global Human Insulin Market, By Product Type (Page No. - 55)
    7.1 Introduction
    7.2 HI Drugs
    7.3 HI Delivery Devices

8 Global Human Insulin Drugs Market, By Type (Page No. - 60)
    8.1 Introduction
    8.2 Insulin Analogs and Biosimilars
           8.2.1 Long-Acting Biosimilars
           8.2.2 Rapid-Acting Biosimilars
           8.2.3 Premixed Biosimilars
    8.3 HI Biologics
           8.3.1 Short-Acting Biologics
           8.3.2 Intermediate-Acting Biologics
           8.3.3 Premixed Biologics

9 Global Human Insulin Drugs Market, By Brand (Page No. - 69)
    9.1 Introduction
    9.2 HI Analogs and Biosimilars
           9.2.1 Lantus
           9.2.2 Novorapid and Novolog
           9.2.3 Humalog
           9.2.4 Other Brands
    9.3 HI Biologics
           9.3.1 Actrapid, Mixtard, and Insulatard
           9.3.2 Humulin
           9.3.3 Insuman

10 Global Human Insulin Market, By Delivery Devices (Page No. - 78)
     10.1 Introduction
     10.2 Syringes
     10.3 Pens
             10.3.1 Disposable Pens
             10.3.2 Reusable Pens
     10.4 Pen Needles
             10.4.1 Standard Pen Needles
             10.4.2 Safety Pen Needles

11 Global Human Insulin Market, By Application (Page No. - 85)
     11.1 Introduction
     11.2 Type I Diabetes
     11.3 Type II Diabetes

12 Human Insulin Market, By Region (Page No. - 90)
     12.1 Introduction
     12.2 North America
             12.2.1 U.S.
             12.2.2 Canada
     12.3 Europe
             12.3.1 Germany
             12.3.2 France
             12.3.3 U.K.
             12.3.4 Rest of Europe (RoE)
     12.4 Asia-Pacific (APAC)
             12.4.1 Japan
             12.4.2 China
             12.4.3 India
             12.4.4 Rest of Asia-Pacific (RoAPAC)
     12.5 Rest of the World (RoW)

13 Competitive Landscape (Page No. - 107)
     13.1 Overview
     13.2 Market Share Analysis
             13.2.1 HI Drugs Market
             13.2.2 HI Delivery Devices Market
     13.3 Competitive Scenario
     13.4 Recent Developments
             13.4.1 Geographical Expansions
             13.4.2 Agreements, Collaborations, and Partnerships
             13.4.3 New Product Launches
             13.4.4 Awareness Programs
             13.4.5 Funding & Scholarships
             13.4.6 Strategic Acquisitions

14 Company Profiles (Page No. - 119)
     14.1 Introduction
             14.1.1 Geographic Benchmarking
             14.1.2 Strategic Benchmarking
                        14.1.2.1 Capacity Building
                        14.1.2.2 Product Development and Commercialization
     14.2 B. Braun Melsungen AG
             14.2.1 Business Overview
             14.2.2 Product Portfolio
             14.2.3 Recent Developments
     14.3 Becton, Dickinson and Company
             14.3.1 Business Overview
             14.3.2 Product Portfolio
             14.3.3 Recent Developments
     14.4 Biocon Limited
             14.4.1 Business Overview
             14.4.2 Product Portfolio
             14.4.3 MnM View
     14.5 Biodel Inc.
             14.5.1 Business Overview
             14.5.2 Product Portfolio
             14.5.3 Recent Developments
     14.6 ELI Lilly and Company
             14.6.1 Business Overview
             14.6.2 Product Portfolio
             14.6.3 Recent Developments
             14.6.4 MnM View
     14.7 Julphar (Also Known as Gulf Pharmaceutical Industries)
             14.7.1 Business Overview
             14.7.2 Product Portfolio
             14.7.3 MnM View
     14.8 NOVO Nordisk A/S
             14.8.1 Business Overview
             14.8.2 Product Portfolio
             14.8.3 Recent Developments
             14.8.4 MnM View
     14.9 Sanofi
             14.9.1 Business Overview
             14.9.2 Product Portfolio
             14.9.3 Recent Developments
             14.9.4 MnM View
     14.10 Wockhardt Limited
             14.10.1 Business Overview
             14.10.2 Product Portfolio
             14.10.3 Recent Developments
     14.11 Ypsomed AG
             14.11.1 Business Overview
             14.11.2 Product Portfolio
             14.11.3 Recent Developments

15 Appendix (Page No. - 152)
     15.1 Insights of Industry Experts
     15.2 Discussion Guide
     15.3 Introducing RT: Real-Time Market Intelligence
     15.4 Available Customizations
     15.5 Related Reports


List of Tables (75 Tables)

Table 1 Key HI Drugs: Year of Patent Expiry
Table 2 Key HI Therapies Under Pipeline Development & Commercialization: 2005-2015
Table 3 HI Pipeline: Major Companies Involved
Table 4 HI Pipeline: Stages of Clinical Trial
Table 5 Global Market Size, By Product Type, 2013–2020 (USD Million)
Table 6 Drugs Market Size, By Region, 2013–2020 (USD Million)
Table 7 Delivery Devices Market Size, By Region, 2013–2020 (USD Million)
Table 8 Global Drugs Market Size, By Type, 2013–2020 (USD Million)
Table 9 Global Insulin Analogs and Biosimilars Market Size, By Type, 2013–2020 (USD Million)
Table 10 Insulin Analogs and Biosimilars Market Size, By Region, 2013–2020 (USD Million)
Table 11 Long-Acting Insulin Analogs and Biosimilars Market Size, By Region, 2013–2020 (USD Million)
Table 12 Rapid-Acting Insulin Analogs and Biosimilars Market Size, By Region, 2013–2020 (USD Million)
Table 13 Premixed Insulin Analogs and Biosimilars Market Size, By Region, 2013–2020 (USD Million)
Table 14 Global Biologics Market Size, By Type, 2013–2020 (USD Million)
Table 15 Biologics Market Size, By Region, 2013–2020 (USD Million)
Table 16 Short-Acting HI Biologics Market Size, By Region, 2013–2020 (USD Million)
Table 17 Intermediate-Acting HI Biologics Market Size, By Region, 2013–2020 (USD Million)
Table 18 Premixed HI Biologics Market Size, By Region, 2013–2020 (USD Million)
Table 19 Global HI Drugs Market Size, By Product Type, 2013–2020 (USD Million)
Table 20 Global Insulin Analogs and Biosimilars Market Size, By Brand, 2013–2020 (USD Million)
Table 21 Insulin Analogs and Biosimilars Market Size, By Region, 2013–2020 (USD Million)
Table 22 Insulin Analogs and Biosimilars Market Size for Lantus, By Region, 2013–2020 (USD Million)
Table 23 Insulin Analogs and Biosimilars Market Size for Novorapid and Novolog, By Region, 2013–2020 (USD Million)
Table 24 Insulin Analogs and Biosimilars Market Size for Humalog, By Region, 2013–2020 (USD Million)
Table 25 Insulin Analogs and Biosimilars Market Size for Other Brands, By Region, 2013–2020 (USD Million)
Table 26 Global HI Biologics Market Size, By Brand, 2013–2020 (USD Million)
Table 27 HI Biologics Market Size, By Region, 2013–2020 (USD Million)
Table 28 HI Biologics Market Size for Actrapid, Mixtard, and Insulatard, By Region, 2013–2020 (USD Million)
Table 29 HI Biologics Market Size for Humulin, By Region, 2013–2020 (USD Million)
Table 30 HI Biologics Market Size for Insuman, By Region, 2013–2020 (USD Million)
Table 31 Global Market Size, By Delivery Device, 2013–2020 (USD Million)
Table 32 HI Syringes Market Size, By Region, 2013–2020 (USD Million)
Table 33 Global HI Pens Market Size, By Product Type, 2013–2020 (USD Million)
Table 34 HI Pens Market Size, By Region, 2013–2020 (USD Million)
Table 35 Disposable HI Pens Market Size, By Region, 2013–2020 (USD Million)
Table 36 Reusable HI Pens Market Size, By Region, 2013–2020 (USD Million)
Table 37 Global HI Pen Needles Market Size, By Product Type, 2013–2020 (USD Million)
Table 38 HI Pen Needles Market Size, By Region, 2013–2020 (USD Million)
Table 39 HI Standard Pen Needles Market Size, By Region, 2013–2020 (USD Million)
Table 40 HI Safety Pen Needles Market Size, By Region, 2013–2020 (USD Million)
Table 41 Global Market Size, By Application, 2013–2020 (USD Million)
Table 42 HI Application Market Size for Type I Diabetes, By Region, 2013–2020 (USD Million)
Table 43 HI Application Market Size for Type Ii Diabetes, By Region, 2013–2020 (USD Million)
Table 44 Market Size, By Region, 2013–2020 (USD Million)
Table 45 North America: Market Size, By Country, 2013–2020 (USD Million)
Table 46 U.S.: Market Size, By Product, 2013–2020 (USD Million)
Table 47 U.S.: Market Size , By Application, 2013–2020 (USD Million)
Table 48 Canada: Market Size, By Product, 2013–2020 (USD Million)
Table 49 Canada: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 50 Europe: Human Insulin Market Size, By Country, 2013–2020 (USD Million)
Table 51 Germany: Human Insulin Market Size, By Product, 2013–2020 (USD Million)
Table 52 Germany: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 53 France: Human Insulin Market Size, By Product, 2013–2020 (USD Million)
Table 54 France: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 55 U.K.: Human Insulin Market Size, By Product, 2013–2020 (USD Million)
Table 56 U.K.: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 57 RoE: Human Insulin Market Size, By Product, 2013–2020 (USD Million)
Table 58 RoE: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 59 APAC: Human Insulin Market Size, By Country, 2013–2020 (USD Million)
Table 60 Japan: Human Insulin Market Size, By Product, 2013–2020 (USD Million)
Table 61 Japan: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 62 China: Human Insulin Market Size, By Product, 2013–2020 (USD Million)
Table 63 China: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 64 India: Human Insulin Market Size, By Product, 2013–2020 (USD Million)
Table 65 India: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 66 RoAPAC: Human Insulin Market Size, By Product, 2013–2020 (USD Million)
Table 67 RoAPAC: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 68 RoW: Human Insulin  Market Size, By Product, 2013–2020 (USD Million)
Table 69 RoW: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 70 Geographical Expansions, 2012–2015
Table 71 Agreements, Collaborations, and Partnerships, 2012–2015
Table 72 New Product Launches and Product Approvals, 2012–2015
Table 73 Awareness Programs, 2012–2015
Table 74 Funding & Scholarships, 2012–2015
Table 75 Strategic Acquisitions, 2012–2015


List of Figures (53 Figures)

Figure 1 Research Design
Figure 2 Bottom-Up Approach
Figure 3 Top-Down Approach
Figure 4 Data Triangulation
Figure 5 Assumptions for the Research Study
Figure 6 Human Insulin Market Share: Key Market Players (2014)
Figure 7 Future Trends: HI Drugs Market, By Type (2015–2020)
Figure 8 Future Trends: Human Insulin Market Size, By Brand (2015–2020)
Figure 9 Future Trends: HI Delivery Devices Market Size, By Type (2015–2020)
Figure 10 Future Trends: Human Insulin Market Share, By Region (2015–2020)
Figure 11 Attractive Growth Opportunities in the Human Insulin Market
Figure 12 North America is Expected to Dominate HI Drugs Market in 2015
Figure 13 Insulin Analogs & Biosimilars  Segment is Expected to Grow the Fastest During Forecast Period
Figure 14 Lantus Was the Best Selling Insulin Brand Across All the Key Geographies in 2014
Figure 15 Insulin Pens to Lead the Overall Growth in HI Delivery Devices Market Till 2020
Figure 16 Asia-Pacific is Poised to Be the Fastest Growing Region in Human Insulin Market Till 2020
Figure 17 Market Evolution of HI Products
Figure 18 Human Insulin Market: Drivers, Restraints, Opportunities, & Challenges
Figure 19 Growth in Diabetic Patient Population Across Key Who Regions (2000–2030)
Figure 20 Proportion of Geriatric Population, By Country (2012 vs 2020)
Figure 21 Global Trend in Government Healthcare Expenditure: Developed vs Developing Countries (2010–2012)
Figure 22 Porter’s Five Forces Analysis (2014): Increasing Number of New Product Manufacturers Increases Market Competition
Figure 23 Drugs to Cover the Largest Market Share of Human Insulin Market Till 2020
Figure 24 U.S. & Europe Lead, Globally, in Terms of the Number of Ongoing Human Insulin-Based Clinical Studies (2015)
Figure 25 Insulin Analogs and Biosimilars Market: Future Trends (2013-2020)
Figure 26 North America to Lead the Premixed Insulin Analogs Market Till 20202
Figure 27 APAC to Grow the Fastest in Human Insulin Biologics Market During the Forecast Period
Figure 28 Lantus to Lead the Insulin Analogs & Biosmilar Market Sales in 2014
Figure 29 Actrapd to Cover the Largest Market Share of Human Insulin Biologics Market in 2015
Figure 30 Insulin Pens Segment is Poised to Grow the Fastest Till 2020
Figure 31 Safety Needles Segment is Expected to Sitness Fastest Market Growth During the Forecast Period
Figure 32 Type 2 Diabetes Application is Poised to Be the Fastest Growing Human Insulin Market Segment During the Study Period
Figure 33 India Will Have Highest Diabetes Population in 2030
Figure 34 Market  Trends: North American Human Insulin Market (2015-2020)
Figure 35 Market Trends: European Human Insulin Market (2015-2020)
Figure 36 Market Trends: Asia-Pacific Human Insulin Market (2015-2020)
Figure 37 Leading Players Adopted the Strategy of Geographic Expansions to Strengthen Their Market Positioning During 2012 to 2015
Figure 38 Global Human Insulin Market Share, By Key Player (2014)
Figure 39 Global HI Drugs Market Ranking, By Key Player (2014)
Figure 40 Global HI Delivery Devices Market Ranking, By Key Player (2014)
Figure 41 Continuous Geographic Expansion is Stimulating Market Competition for Capacity Building Among Key Players
Figure 42 Geographic Revenue Mix of the Top 5 Market Players* (2014)
Figure 43 Leading Companies are Focusing on Capacity Building to Strengthen Their Product Development & Manufacturing Base
Figure 44 Leading HI Manufacturers are Focusing on Product Commercialization to Strengthen Their Market Position
Figure 45 B. Braun Melsungen AG: Company Snapshot
Figure 46 Becton, Dickinson and Company: Company Snapshot
Figure 47 Biocon Limited: Company Snapshot
Figure 48 ELI Lilly and Company: Company Snapshot
Figure 49 Julphar: Company Snapshot
Figure 50 NOVO Nordisk A/S: Company Snapshot
Figure 51 Sanofi: Company Snapshot
Figure 52 Wockhardt Limited: Company Snapshot
Figure 53 Ypsomed AG: Company Snapshot

The global human insulin market is poised to reach ~USD 39.13 Billion by 2020 growing at a CAGR of 8.1% from 2015 to 2020. Market growth can be attributed to factors such as growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. However, stringent regulatory requirements for product approval are restraining the growth of market. In addition, high product manufacturing costs is posing significant challenges for market growth.

On the basis of product, the human insulin market is classified into two major segments— drugs and delivery devices. Human insulin drugs segment is expected to account for the largest share of the global market, by product, in 2015. Its large share is propelled by factors such as increasing diabetic population across globe, growing R&D for drug discovery & development, rising proportion of aging population in developed countries, increasing market accessibility of generic human insulin products worldwide, and rising government initiatives to support the development and commercialization of effective biosimilars.

On the basis of product type, the human insulin delivery devices market is classified into three segments—pens, pen needles, and syringes. The pens segment is expected to account for the largest market share in 2015; it is poised to be the fastest-growing segment during the next five years. Its high growth can be attributed to growing market focus of pen manufacturers on emerging countries such as China, India, & Brazil; significant medical reimbursements offered for human insulin pens across mature markets such as the U.S. & Europe; and continuous pipeline development & product commercialization of innovative human insulin pens.

Geographically, the market is classified into four regions—North America, Europe, Asia-Pacific, and the Rest of the World. In 2015, North America is estimated to dominate the global human insulin market. The Asia-Pacific market is poised to grow the fastest, during the forecast period, owing to growing diabetes prevalence in APAC (coupled with large diabetic & pre-diabetic patient population), strengthening distribution networks of global product manufacturers in the region, evolving regulatory framework for marketing approvals & medical reimbursements, continued expansion of advanced medical facilities in emerging countries (such as China & India), and rising public awareness related to benefits offered by human insulin in diabetes treatment.

Geography expansion and product development are the key strategies adopted by major players to strengthen their positions in the global market. Moreover, strategies such as partnerships, agreements, collaborations, awareness campaigns, and research funding & grants were also adopted by a significant number of market players to strengthen their product portfolios and expand their distribution networks in the global human insulin market.

Sanofi (France), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Biocon Ltd. (India), Julphar (U.A.E.), Ypsomed AG (Switzerland), Becton, Dickinson and Company (U.S.), Wockhardt Ltd. (India), B. Braun Meselgen AG (Switzerland), and Biodel Inc. (U.S.) are few of the key players operating in the global human insulin market.

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Biotechnology Markets on KnowledgeStore
Request Demo Now